PDL BioPharma Net Income 2006-2020 | PDLI

PDL BioPharma net income from 2006 to 2020. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
PDL BioPharma Annual Net Income
(Millions of US $)
2020 $
2019 $-70
2018 $-69
2017 $111
2016 $64
2015 $333
2014 $322
2013 $265
2012 $212
2011 $199
2010 $92
2009 $190
2008 $68
2007 $-21
2006 $-130
2005 $-167
PDL BioPharma Quarterly Net Income
(Millions of US $)
2020-12-31
2020-06-30 $-50
2020-03-31 $-32
2019-12-31 $-55
2019-09-30 $-18
2019-06-30 $-4
2019-03-31 $7
2018-12-31 $16
2018-09-30 $26
2018-06-30 $-112
2018-03-31 $2
2017-12-31 $22
2017-09-30 $21
2017-06-30 $60
2017-03-31 $7
2016-12-31 $-10
2016-09-30 $14
2016-06-30 $4
2016-03-31 $56
2015-12-31 $101
2015-09-30 $69
2015-06-30 $78
2015-03-31 $84
2014-12-31 $55
2014-09-30 $102
2014-06-30 $92
2014-03-31 $73
2013-12-31 $61
2013-09-30 $56
2013-06-30 $94
2013-03-31 $53
2012-12-31 $49
2012-09-30 $49
2012-06-30 $74
2012-03-31 $40
2011-12-31 $39
2011-09-30 $46
2011-06-30 $70
2011-03-31 $45
2010-12-31 $-24
2010-09-30 $40
2010-06-30 $50
2010-03-31 $26
2009-12-31 $29
2009-09-30 $46
2009-06-30 $77
2009-03-31 $37
2008-12-31 $41
2008-09-30 $56
2008-06-30 $34
2008-03-31 $-62
2007-12-31 $-16
2007-09-30 $-6
2007-06-30 $11
2007-03-31 $-11
2006-12-31 $-90
2006-09-30 $-7
2006-06-30 $-7
2006-03-31 $-26
2005-12-31 $-34
2005-09-30 $-45
2005-06-30 $-3
2005-03-31 $-84
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00